Avalo Therapeutics Inc (AVTX)vsBeiGene, Ltd. (ONC)
AVTX
Avalo Therapeutics Inc
$13.95
+3.72%
HEALTHCARE · Cap: $248.44M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 2782730% more annual revenue ($5.34B vs $192,000). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
AVTX
Avoid24
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVTX.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.7% — below average capital efficiency
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AVTX
The strongest argument for AVTX centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : AVTX
The primary concerns for AVTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
AVTX profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
AVTX carries more volatility with a beta of 0.89 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 24/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avalo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Avalo Therapeutics Inc is a pioneering clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved conditions, particularly in the realm of immunological regulation. With a robust pipeline of proprietary candidates targeting serious diseases with significant unmet medical needs, Avalo leverages its deep expertise in disease mechanisms to advance its therapeutic programs through rigorous clinical trials. The company's dedication to scientific innovation and a patient-centric approach positions it to navigate the complexities of the biopharmaceutical industry effectively, with the goal of delivering transformative therapies to improve patient outcomes.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?